✦ LIBER ✦
29LB1 Late Breaking ORAL Final safety, pharmacokinetic and antitumor activity results of a phase I study of YM155, a novel survivin inhibitor, when administered by 168 hour continuous infusion
✍ Scribed by A.C. Mita; S. Antonia; L.D. Lewis; J.J. Mahany; N.J. Reddy; A. Ricart; E. Till; D. Buell; A.T. Keating; A.W. Tolcher
- Book ID
- 118623658
- Publisher
- Elsevier Science
- Year
- 2006
- Tongue
- English
- Weight
- 58 KB
- Volume
- 4
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.